We are live on ! Find out more
DYN icon

Dyne Therapeutics

227 hedge funds and large institutions have $3.4B invested in Dyne Therapeutics in 2026 Q1 according to their latest regulatory filings, with 42 funds opening new positions, 100 increasing their positions, 60 reducing their positions, and 45 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 100 | Existing positions reduced: 60

2% less capital invested

Capital invested by funds: $3.48B → $3.4B (-$78.1M)

7% less first-time investments, than exits

New positions opened: 42 | Existing positions closed: 45

2% less funds holding

Funds holding: 232227 (-5)

10.74% less ownership

Funds ownership: 124.57%113.83% (-11%)

29% less funds holding in top 10

Funds holding in top 10: 75 (-2)

83% less call options, than puts

Call options by funds: $769K | Put options by funds: $4.47M

Holders
227
Holders Change
-5
Holders Change %
-2.16%
% of All Funds
2.79%
Holding in Top 10
5
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-28.57%
% of All Funds
0.06%
New
42
Increased
100
Reduced
60
Closed
45
Calls
$769K
Puts
$4.47M
Net Calls
-$3.7M
Net Calls Change
-$596K
Name Holding Trade Value Shares
Change
Change in
Stake
TD Asset Management
51
TD Asset Management
Ontario, Canada
$9.6M +$1.89M +109,556 +26%
SC
52
Stempoint Capital
New York
$9.18M -$5.68M -329,125 -39%
Ensign Peak Advisors
53
Ensign Peak Advisors
Utah
$9M
UOWF
54
University of Wisconsin Foundation
Wisconsin
$8.79M +$1.17M +67,995 +16%
AG
55
Algert Global
California
$8.24M +$3.16M +183,160 +68%
Raymond James Financial
56
Raymond James Financial
Florida
$8.19M -$1.36M -78,694 -15%
WA
57
Wasatch Advisors
Utah
$8.04M +$633K +36,708 +9%
ClearBridge Investments
58
ClearBridge Investments
New York
$7.31M -$78.8K -4,569 -1%
Bank of New York Mellon
59
Bank of New York Mellon
New York
$7.28M +$830K +48,119 +14%
UBS Group
60
UBS Group
Switzerland
$6.9M -$7.19K -417 -0.1%
New York State Common Retirement Fund
61
New York State Common Retirement Fund
New York
$6.05M +$4.38M +254,235 +321%
Fisher Asset Management
62
Fisher Asset Management
Washington
$5.86M +$1.26M +72,986 +29%
CCM
63
Catalio Capital Management
New York
$5.13M -$4.08M -236,761 -46%
TAM
64
TFG Asset Management
Cayman Islands
$4.68M +$175K +10,135 +4%
Qube Research & Technologies (QRT)
65
Qube Research & Technologies (QRT)
United Kingdom
$4.59M -$2.75M -159,287 -39%
Invesco
66
Invesco
Georgia
$4.51M +$1.92M +111,257 +81%
UBS AM
67
UBS AM
Illinois
$4.34M +$428K +24,794 +12%
Swiss National Bank
68
Swiss National Bank
Switzerland
$4.14M +$96.6K +5,600 +3%
Deutsche Bank
69
Deutsche Bank
Germany
$4.01M +$432K +25,043 +13%
Citadel Advisors
70
Citadel Advisors
Florida
$3.65M -$16.7M -970,480 -83%
SC
71
SummitTX Capital
Texas
$3.56M -$812K -47,088 -19%
RhumbLine Advisers
72
RhumbLine Advisers
Massachusetts
$3.39M +$210K +12,203 +7%
PP
73
PDT Partners
New York
$3.32M
Rafferty Asset Management
74
Rafferty Asset Management
New York
$3.32M -$877K -50,858 -22%
HS
75
HighVista Strategies
Massachusetts
$3.32M +$2.13M +123,286 +207%

DYN Hedge Fund Activity: Q1 2026 in Review

227 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Dyne Therapeutics (DYN) for Q1 2026, worth a combined $3.4B — down 2.2% from $3.48B a quarter earlier.

Sellers outnumbered buyers: 45 funds closed out of DYN and 42 opened new positions — a net loss of 3 holders — while 60 trimmed existing stakes and 100 added.

The largest buyer was T. Rowe Price Investment Management, adding an estimated $228M. The largest seller was Adage Capital Partners, cutting an estimated $71.9M.

  • 227 institutional investors held Dyne Therapeutics (DYN) as of Q1 2026, down from 232 in Q4 2025.
  • Funds reported $3.4B of Dyne Therapeutics stock for Q1 2026, down 2.2% quarter-over-quarter.
  • 42 funds opened new Dyne Therapeutics positions in Q1 2026 and 45 closed out, a net change of -3 holders.
  • The largest Dyne Therapeutics buyer in Q1 2026 was T. Rowe Price Investment Management, an estimated $228M added.
  • The largest Dyne Therapeutics seller in Q1 2026 was Adage Capital Partners, an estimated $71.9M sold.

Based on aggregated 13F filings for Q1 2026.